Short answer
CareDx, Inc. (CDNA) filed an 8-K current report with the SEC on February 25, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Q4 2025 earnings released Feb 24, 2026: full results in Exhibit 99.1.
CareDx, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 2025 earnings released Feb 24, 2026: full results in Exhibit 99.1
- Quarter ended Dec 31, 2025 covered; specific financials available in attached press release
Item 5.02 · Departure/Election of Directors or Officers
- Keith Kennedy (age 56) elevated from COO to CFO+COO dual role, effective Feb 26, 2026: adds financial oversight to existing operational responsibilities
- Kennedy brings prior CFO experience at Veracyte and PharmaLogic; CFA + CPA credentials signal strong financial controls background
- Outgoing CFO Nathan Smith resigned for personal reasons Feb 25, 2026: explicitly not due to disagreement over financials or disclosures
- Smith separation package: 9 months base salary (lump sum), $91,643 bonus, 9 months COBRA, and 5,840 RSUs vested pro rata
- Dual CFO/COO role under one executive is a notable structural consolidation: investors should monitor whether this signals cost discipline or leadership depth concerns
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation posted to website, current as of Feb 24, 2026
- Reg FD disclosure ensures institutional and retail investors receive simultaneous access to material information
- Company explicitly disclaims future update obligations: presentation may become stale quickly
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other CareDx, Inc. 8-K filings
Get the next CDNA 8-K as it lands
Follow CDNA for push alerts, or ask the research agent what this filing means.